Becton, Dickinson and Company $BDX Stock Holdings Lessened by Sumitomo Mitsui Trust Group Inc.

Key Points

• Sumitomo Mitsui Trust Group trimmed its stake in Becton, Dickinson by 4.4% in Q4, holding 665,496 shares (about $129.15 million or ~0.23% of the company) after selling 30,532 shares.
• BDX reported $2.91 EPS (beating the $2.81 consensus) but missed revenue at $4.49 billion versus $5.15 billion; management set FY2026 guidance of 12.35–12.65 EPS and analysts’ consensus rating is “Hold” with an average price target of $189.69.
• The company authorized a $10.0 million share buyback plan and pays a quarterly dividend of $1.05 (annualized $4.20, yield ~2.7%), while institutional investors own roughly 86.97% of the stock.

Sumitomo Mitsui Trust Group Inc. lowered its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 4.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 665,496 shares of the medical instruments supplier's stock after selling 30,532 shares during the period. Sumitomo Mitsui Trust Group Inc. owned approximately 0.23% of Becton, Dickinson and Company worth $129,153,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of BDX. Wellington Management Group LLP increased its holdings in shares of Becton, Dickinson and Company by 9,056.3% in the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier's stock valued at $979,290,000 after buying an additional 5,174,944 shares in the last quarter. First Eagle Investment Management LLC increased its holdings in shares of Becton, Dickinson and Company by 13.8% in the third quarter. First Eagle Investment Management LLC now owns 9,994,408 shares of the medical instruments supplier's stock valued at $1,870,653,000 after buying an additional 1,208,218 shares in the last quarter. Veritas Asset Management LLP increased its holdings in shares of Becton, Dickinson and Company by 40.6% in the third quarter. Veritas Asset Management LLP now owns 2,954,898 shares of the medical instruments supplier's stock valued at $553,068,000 after buying an additional 852,854 shares in the last quarter. Rakuten Investment Management Inc. bought a new position in shares of Becton, Dickinson and Company in the third quarter valued at $152,931,000. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Becton, Dickinson and Company by 7.5% in the third quarter. Massachusetts Financial Services Co. MA now owns 9,150,584 shares of the medical instruments supplier's stock valued at $1,712,715,000 after buying an additional 636,138 shares in the last quarter. Institutional investors own 86.97% of the company's stock.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX opened at $155.36 on Tuesday. The company's fifty day moving average is $170.01 and its two-hundred day moving average is $185.18. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The company has a market cap of $44.24 billion, a P/E ratio of 25.34, a price-to-earnings-growth ratio of 10.97 and a beta of 0.29.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The company had revenue of $4.49 billion for the quarter, compared to the consensus estimate of $5.15 billion. During the same period in the previous year, the business earned $3.43 EPS. The company's revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Equities analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its board has approved a stock repurchase plan on Tuesday, January 27th that authorizes the company to buyback $10.00 million in outstanding shares. This buyback authorization authorizes the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock buyback plans are often an indication that the company's leadership believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Tuesday, March 10th were issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Tuesday, March 10th. Becton, Dickinson and Company's payout ratio is currently 68.52%.

Insider Buying and Selling at Becton, Dickinson and Company

In other news, Director Bertram L. Scott sold 953 shares of the business's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total transaction of $174,027.33. Following the transaction, the director directly owned 36,763 shares in the company, valued at $6,713,291.43. The trade was a 2.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael David Garrison sold 1,610 shares of the business's stock in a transaction on Thursday, January 15th. The shares were sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president owned 12,095 shares in the company, valued at approximately $2,509,228.70. This represents a 11.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 2,713 shares of company stock worth $536,881. 0.40% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on BDX. Wells Fargo & Company dropped their price target on Becton, Dickinson and Company from $184.00 to $157.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 10th. Jefferies Financial Group cut their target price on shares of Becton, Dickinson and Company from $220.00 to $190.00 and set a "buy" rating on the stock in a research note on Tuesday, February 10th. Royal Bank Of Canada set a $172.00 target price on shares of Becton, Dickinson and Company in a research note on Tuesday, February 10th. Zacks Research raised shares of Becton, Dickinson and Company from a "strong sell" rating to a "hold" rating in a research note on Friday. Finally, JPMorgan Chase & Co. cut their target price on shares of Becton, Dickinson and Company from $190.00 to $175.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 10th. Six equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $189.69.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.